All Stories

  1. Fear of falling and falls in people with multiple sclerosis: A literature review

    Article • Multiple Sclerosis and Related Disorders, January 2021, Elsevier

    Professor Tjalf Ziemssen

  2. On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device—A Proof of Concept Study in Multiple Sclerosis

    Article • Journal of Clinical Medicine, October 2020, MDPI AG

    Professor Tjalf Ziemssen

  3. The Transitional Phase of Multiple Sclerosis: The concept of PANGAEA 2.0 EVOLUTION Study

    Article • Multiple Sclerosis and Related Disorders, September 2020, Elsevier

    Professor Tjalf Ziemssen

  4. Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients

    Article • Proceedings of the National Academy of Sciences, August 2020, Proceedings of the National Academy of Sciences

    Professor Tjalf Ziemssen

  5. Patient‐ versus physician‐reported relapses in multiple sclerosis: insights from a large observational study

    Article • European Journal of Neurology, August 2020, Wiley

    Professor Tjalf Ziemssen

  6. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

    Article • CNS Drugs, July 2020, Springer Science + Business Media

    Professor Tjalf Ziemssen

  7. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA

    Article • JMIR Research Protocols, July 2020, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  8. How to reduce the delay of diagnosing secondary progression in multiple sclerosis

    Article • Multiple Sclerosis Journal, July 2020, SAGE Publications

    Professor Tjalf Ziemssen

  9. A possible role of the norepinephrine system during sequential cognitive flexibility – Evidence from EEG and pupil diameter data

    Article • Cortex, July 2020, Elsevier

    Professor Tjalf Ziemssen

  10. Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study

    Article • Patient Preference and Adherence, May 2020, Taylor & Francis

    Professor Tjalf Ziemssen

  11. Visual Feedback and Postural Control in Multiple Sclerosis

    Article • Journal of Clinical Medicine, April 2020, MDPI AG

    Professor Tjalf Ziemssen

  12. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA (Preprint)

    Article • April 2020, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  13. A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm

    Article • JMIR Medical Informatics, April 2020, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  14. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis

    Article • Scientific Reports, April 2020, Springer Science + Business Media

    Professor Tjalf Ziemssen

  15. The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

    Article • Journal of Medical Internet Research, March 2020, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  16. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study

    Article • Journal of Medical Internet Research, February 2020, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  17. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis

    Article • Multiple Sclerosis and Related Disorders, February 2020, Elsevier

    Professor Tjalf Ziemssen

  18. How to Implement Adherence-Promoting Programs in Clinical Practice? A Discrete Choice Experiment on Physicians’ Preferences

    Article • Patient Preference and Adherence, February 2020, Taylor & Francis

    Professor Tjalf Ziemssen

  19. The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (Preprint)

    Article • January 2020, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  20. Correction to: Differentiating societal costs of disability worsening in multiple sclerosis

    Article • Journal of Neurology, January 2020, Springer Science + Business Media

    Professor Tjalf Ziemssen

  21. Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients

    Article • Therapeutic Advances in Neurological Disorders, January 2020, SAGE Publications

    Professor Tjalf Ziemssen

  22. Differentiating societal costs of disability worsening in multiple sclerosis

    Article • Journal of Neurology, December 2019, Springer Science + Business Media

    Professor Tjalf Ziemssen

  23. Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?

    Article • Hormone and Metabolic Research, December 2019, Thieme Publishing Group

    Professor Tjalf Ziemssen

  24. Molecular biomarkers in multiple sclerosis

    Article • Journal of Neuroinflammation, December 2019, Springer Science + Business Media

    Professor Tjalf Ziemssen

  25. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

    Article • Multiple Sclerosis Journal, November 2019, SAGE Publications

    Professor Tjalf Ziemssen

  26. Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

    Article • Multiple Sclerosis Journal, November 2019, SAGE Publications

    Professor Tjalf Ziemssen

  27. Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

    Article • Multiple Sclerosis Journal, November 2019, SAGE Publications

    Professor Tjalf Ziemssen

  28. Remote-Sensoring – neue Optionen des Progressionsmonitorings bei Multipler Sklerose

    Article • Der Nervenarzt, October 2019, Springer Science + Business Media

    Professor Tjalf Ziemssen

  29. Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis

    Article • Journal of Molecular Medicine, August 2019, Springer Science + Business Media

    Professor Tjalf Ziemssen

  30. Review: Patient-reported outcomes in multiple sclerosis care

    Article • Multiple Sclerosis and Related Disorders, August 2019, Elsevier

    Professor Tjalf Ziemssen

  31. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

    Article • Journal of Neurology, July 2019, Springer Science + Business Media

    Professor Tjalf Ziemssen

  32. Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients

    Article • July 2019, SAGE Publications

    Professor Tjalf Ziemssen

  33. Response to: Kobayashi et al.: “Erythroblast appearance associated with natalizumab” Multiple Sclerosis and Related Disorders 2019

    Article • Multiple Sclerosis and Related Disorders, July 2019, Elsevier

    Professor Tjalf Ziemssen

  34. Early central vs. peripheral immunological and neurobiological effects of fingolimod—a longitudinal study

    Article • Journal of Molecular Medicine, June 2019, Springer Science + Business Media

    Professor Tjalf Ziemssen

  35. How the depth of processing modulates emotional interference – evidence from EEG and pupil diameter data

    Article • Cognitive Affective & Behavioral Neuroscience, June 2019, Springer Science + Business Media

    Professor Tjalf Ziemssen

  36. Response to Hyun J.W. et al. “Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis”

    Article • Multiple Sclerosis Journal, May 2019, SAGE Publications

    Professor Tjalf Ziemssen

  37. Spectral Analysis of Heart Rate Variability: Time Window Matters

    Article • Frontiers in Neurology, May 2019, Frontiers

    Professor Tjalf Ziemssen

  38. On the interrelation of 1/f neural noise and norepinephrine system activity during motor response inhibition

    Article • Journal of Neurophysiology, May 2019, American Physiological Society

    Professor Tjalf Ziemssen

  39. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS

    Article • Neurology Neuroimmunology & Neuroinflammation, April 2019, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  40. Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”

    Article • Multiple Sclerosis Journal, April 2019, SAGE Publications

    Professor Tjalf Ziemssen

  41. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence

    Article • Neurodegenerative Disease Management, April 2019, Future Medicine

    Professor Tjalf Ziemssen

  42. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

    Article • Frontiers in Neurology, March 2019, Frontiers

    Professor Tjalf Ziemssen

  43. Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany

    Article • Neurology Neuroimmunology & Neuroinflammation, March 2019, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  44. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

    Article • Multiple Sclerosis Journal, February 2019, SAGE Publications

    Professor Tjalf Ziemssen

  45. The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review

    Article • Frontiers in Neurology, February 2019, Frontiers

    Professor Tjalf Ziemssen

  46. Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition

    Article • Brain Structure and Function, January 2019, Springer Science + Business Media

    Professor Tjalf Ziemssen

  47. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

    Article • JAMA, January 2019, American Medical Association (AMA)

    Professor Tjalf Ziemssen

  48. Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting

    Article • Therapeutic Advances in Chronic Disease, January 2019, SAGE Publications

    Professor Tjalf Ziemssen

  49. Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies

    Article • Journal of Central Nervous System Disease, January 2019, SAGE Publications

    Professor Tjalf Ziemssen, Ute Essner

  50. Exploring individual multiple sclerosis lesion volume change over time: Development of an algorithm for the analyses of longitudinal quantitative MRI measures

    Article • NeuroImage Clinical, January 2019, Elsevier

    Professor Tjalf Ziemssen

  51. How minimal variations in neuronal cytoskeletal integrity modulate cognitive control

    Article • NeuroImage, January 2019, Elsevier

    Professor Tjalf Ziemssen

  52. Multiple sclerosis registries in Europe – An updated mapping survey

    Article • Multiple Sclerosis and Related Disorders, January 2019, Elsevier

    Professor Tjalf Ziemssen

  53. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

    Article • CNS Drugs, December 2018, Springer Science + Business Media

    Professor Tjalf Ziemssen

  54. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients

    Article • Frontiers in Immunology, November 2018, Frontiers

    Professor Tjalf Ziemssen

  55. International consensus on quality standards for brain health-focused care in multiple sclerosis

    Article • Multiple Sclerosis Journal, November 2018, SAGE Publications

    Professor Tjalf Ziemssen

  56. Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks

    Article • Neurology, October 2018, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  57. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

    Article • CNS Drugs, September 2018, Springer Science + Business Media

    Professor Tjalf Ziemssen

  58. Sudomotor Testing of Diabetes Polyneuropathy

    Article • Frontiers in Neurology, September 2018, Frontiers

    Professor Tjalf Ziemssen

  59. Predictors of response to opicinumab in acute optic neuritis

    Article • Annals of Clinical and Translational Neurology, August 2018, Wiley

    Professor Tjalf Ziemssen

  60. Wissensstand von Patienten und Gesundheitsberufen über Diabetes-bedingte Augenerkrankungen (Risikofaktoren, Früherkennung und Behandlung)

    Article • Diabetologie und Stoffwechsel, June 2018, Thieme Publishing Group

    Professor Tjalf Ziemssen

  61. Comment on Y.D. Fragoso et al.: “Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod” Multiple Sclerosis and Related Disorders 2017

    Article • Multiple Sclerosis and Related Disorders, May 2018, Elsevier

    Professor Tjalf Ziemssen

  62. Letter to the editor to the paper: “Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis”

    Article • Multiple Sclerosis and Related Disorders, May 2018, Elsevier

    Professor Tjalf Ziemssen

  63. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

    Article • The Lancet Neurology, May 2018, Elsevier

    Professor Tjalf Ziemssen

  64. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology

    Article • Journal of Autoimmunity, March 2018, Elsevier

    Professor Tjalf Ziemssen, Prof. Dr. Jens Pietzsch

  65. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

    Article • The Lancet, March 2018, Elsevier

    Professor Tjalf Ziemssen, prof aksel siva

  66. Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach

    Article • Expert Opinion on Drug Safety, February 2018, Taylor & Francis

    Professor Tjalf Ziemssen

  67. Dual-Tasking in Multiple Sclerosis – Implications for a Cognitive Screening Instrument

    Article • Frontiers in Human Neuroscience, January 2018, Frontiers

    Professor Tjalf Ziemssen

  68. An Innovative Technique to Assess Spontaneous Baroreflex Sensitivity with Short Data Segments: Multiple Trigonometric Regressive Spectral Analysis

    Article • Frontiers in Physiology, January 2018, Frontiers

    Professor Tjalf Ziemssen

  69. Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures

    Article • Frontiers in Neurology, January 2018, Frontiers

    Professor Tjalf Ziemssen

  70. Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany

    Article • Therapeutic Advances in Neurological Disorders, January 2018, SAGE Publications

    Professor Tjalf Ziemssen

  71. Multi-component relaxation in clinically isolated syndrome: Lesion myelination may predict multiple sclerosis conversion

    Article • NeuroImage Clinical, January 2018, Elsevier

    Henning Schmitz-Peiffer, Professor Tjalf Ziemssen

  72. Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis

    Article • Therapeutic Advances in Neurological Disorders, January 2018, SAGE Publications

    Professor Tjalf Ziemssen

  73. Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

    Article • Therapeutic Advances in Neurological Disorders, January 2018, SAGE Publications

    Professor Tjalf Ziemssen

  74. Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

    Article • Neurotherapeutics, December 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  75. Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod

    Article • Clinical Pharmacology in Drug Development, December 2017, Wiley

    Professor Tjalf Ziemssen

  76. Perceptions on the value of bodily functions in multiple sclerosis

    Article • Acta Neurologica Scandinavica, December 2017, Wiley

    Professor Tjalf Ziemssen

  77. The role of phasic norepinephrine modulations during task switching: evidence for specific effects in parietal areas

    Article • Referate und Beiträge zur Anatomie und Entwickelungsgeschichte, October 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  78. Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

    Article • Frontiers in Neuroscience, October 2017, Frontiers

    Professor Tjalf Ziemssen

  79. Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up

    Article • Frontiers in Physiology, October 2017, Frontiers

    Professor Tjalf Ziemssen

  80. Response to: S. Sega-Jazbec et al.: “Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis” Multiple Sclerosis and Related Disorders 2017

    Article • Multiple Sclerosis and Related Disorders, October 2017, Elsevier

    Professor Tjalf Ziemssen

  81. Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen

    Article • Diabetes aktuell, October 2017, Thieme Publishing Group

    Professor Tjalf Ziemssen

  82. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis

    Article • Expert Opinion on Pharmacotherapy, September 2017, Taylor & Francis

    Professor Tjalf Ziemssen

  83. Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen

    Article • DMW - Deutsche Medizinische Wochenschrift, September 2017, Thieme Publishing Group

    Professor Tjalf Ziemssen

  84. Natalizumab during pregnancy and lactation

    Article • Multiple Sclerosis Journal, August 2017, SAGE Publications

    Professor Tjalf Ziemssen

  85. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

    Article • Journal of Neuroinflammation, August 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  86. Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion

    Article • Expert Opinion on Pharmacotherapy, August 2017, Taylor & Francis

    Professor Tjalf Ziemssen

  87. Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

    Article • Multiple Sclerosis Journal, August 2017, SAGE Publications

    Professor Tjalf Ziemssen

  88. Patients’ preferences for involvement in the decision-making process for treating diabetic retinopathy

    Article • BMC Ophthalmology, August 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  89. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

    Article • Therapeutic Advances in Neurological Disorders, August 2017, SAGE Publications

    Professor Tjalf Ziemssen

  90. Real-world-Evidenz

    Article • Der Nervenarzt, August 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  91. Demands on response inhibition processes determine modulations of theta band activity in superior frontal areas and correlations with pupillometry – Implications for the norepinephrine system during inhibitory control

    Article • NeuroImage, August 2017, Elsevier

    Professor Tjalf Ziemssen

  92. Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease

    Article • Scientific Reports, August 2017, Nature

    Professor Tjalf Ziemssen

  93. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

    Article • Multiple Sclerosis Journal, July 2017, SAGE Publications

    Professor Tjalf Ziemssen

  94. To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question

    Article • Expert Review of Neurotherapeutics, June 2017, Taylor & Francis

    Professor Tjalf Ziemssen, Dr Emanuele D'amico

  95. Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

    Article • PLoS ONE, May 2017, PLOS

    Professor Tjalf Ziemssen

  96. ActiGait implantable drop foot stimulator in multiple sclerosis: a new indication

    Article • Journal of Neurosurgery, May 2017, Journal of Neurosurgery Publishing Group (JNSPG)

    Professor Tjalf Ziemssen

  97. A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity

    Article • Nature Immunology, April 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  98. Multiple sclerosis in the real world: A systematic review of fingolimod as a case study

    Article • Autoimmunity Reviews, April 2017, Elsevier

    Professor Tjalf Ziemssen

  99. The norepinephrine system shows information-content specific properties during cognitive control – Evidence from EEG and pupillary responses

    Article • NeuroImage, April 2017, Elsevier

    Professor Tjalf Ziemssen

  100. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

    Article • The Lancet Neurology, April 2017, Elsevier

    Professor Tjalf Ziemssen, Dr Tomas Kalincik

  101. Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment

    Article • BMC Neurology, March 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  102. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

    Article • The Lancet Neurology, March 2017, Elsevier

    Professor Tjalf Ziemssen

  103. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation

    Article • Journal of Neuroinflammation, February 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  104. Treatment optimization in multiple sclerosis: how do we apply emerging evidence?

    Article • Expert Review of Clinical Immunology, February 2017, Taylor & Francis

    Professor Tjalf Ziemssen

  105. Adrenal medullary dysfunction as a feature of obesity

    Article • International Journal of Obesity, February 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  106. The norepinephrine system and its relevance for multi-component behavior

    Article • NeuroImage, February 2017, Elsevier

    Professor Tjalf Ziemssen

  107. Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study

    Article • BMC Neurology, January 2017, Springer Science + Business Media

    Professor Tjalf Ziemssen

  108. Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson’s Disease (CAPTURE PD): Protocol for a Multicenter Study

    Article • Frontiers in Neurology, January 2017, Frontiers

    Professor Tjalf Ziemssen

  109. Long-term safety and tolerability of glatiramer acetate 20 mg in the treatment of relapsing forms of multiple sclerosis

    Article • Expert Opinion on Drug Safety, December 2016, Taylor & Francis

    Professor Tjalf Ziemssen

  110. Immunomodulatory treatments and cognition in MS

    Article • Acta Neurologica Scandinavica, September 2016, Wiley

    Professor Tjalf Ziemssen

  111. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis

    Article • JAMA Neurology, September 2016, American Medical Association (AMA)

    Professor Tjalf Ziemssen

  112. The norepinephrine system affects specific neurophysiological subprocesses in the modulation of inhibitory control by working memory demands

    Article • Human Brain Mapping, August 2016, Wiley

    Professor Tjalf Ziemssen

  113. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod

    Article • BMC Neurology, August 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  114. Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach

    Article • BMC Neurology, August 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  115. Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

    Article • BMC Neurology, July 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  116. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

    Article • BMC Neurology, July 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  117. Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ)

    Article • Deutsche Zeitschrift für Nervenheilkunde, July 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  118. Hes3 expression in the adult mouse brain is regulated during demyelination and remyelination

    Article • Brain Research, July 2016, Elsevier

    Professor Tjalf Ziemssen

  119. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

    Article • Journal of Neuroinflammation, June 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  120. The importance of collecting structured clinical information on multiple sclerosis

    Article • BMC Medicine, May 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  121. 6-sulpho LacNAc+dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system

    Article • Neuropathology and Applied Neurobiology, May 2016, Wiley

    Professor Tjalf Ziemssen

  122. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation

    Article • Proceedings of the National Academy of Sciences, May 2016, Proceedings of the National Academy of Sciences

    Professor Tjalf Ziemssen

  123. Laquinimod in the treatment of relapsing remitting multiple sclerosis

    Article • Expert Opinion on Drug Metabolism & Toxicology, May 2016, Taylor & Francis

    Professor Tjalf Ziemssen

  124. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS

    Article • Neurology Neuroimmunology & Neuroinflammation, April 2016, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  125. Comparison of baroreflex sensitivity estimated from ECG R–R and inter-systolic intervals obtained by finger plethysmography and radial tonometry

    Article • Journal of Neural Transmission, March 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  126. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey

    Article • Therapeutic Advances in Neurological Disorders, March 2016, SAGE Publications

    Professor Tjalf Ziemssen

  127. Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie

    Article • Der Nervenarzt, February 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  128. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients

    Article • Deutsche Zeitschrift für Nervenheilkunde, February 2016, Springer Science + Business Media

    Professor Tjalf Ziemssen

  129. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid

    Article • Nature, February 2016, Nature

    Professor Tjalf Ziemssen

  130. Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol

    Article • JMIR Research Protocols, February 2016, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  131. Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System

    Article • Interactive Journal of Medical Research, January 2016, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  132. Limited Time from the Diabetes Patients' Perspective: Need for Conversation with the Eye Specialist

    Article • Ophthalmologica, January 2016, Karger Publishers

    Professor Tjalf Ziemssen

  133. Optimizing treatment success in multiple sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, December 2015, Springer Science + Business Media

    Professor Tjalf Ziemssen

  134. Physician–patient communication skills: e-tools

    Article • Neurodegenerative Disease Management, December 2015, Future Medicine

    Professor Tjalf Ziemssen

  135. Welchen Effekt hat das Washout bei der Umstellung von Natalizumab auf Fingolimod?

    Article • InFo Neurologie + Psychiatrie, November 2015, Springer Science + Business Media

    Professor Tjalf Ziemssen

  136. Patient mit Small-Fiber-Neuropathie — das können Sie tun

    Article • MMW - Fortschritte der Medizin, November 2015, Springer Science + Business Media

    Professor Tjalf Ziemssen

  137. Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)

    Article • Neurology and Therapy, October 2015, Springer Science + Business Media

    Professor Tjalf Ziemssen

  138. Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate

    Article • BMC Neurology, October 2015, Springer Science + Business Media

    Professor Tjalf Ziemssen

  139. Recognition and treatment of autonomic disturbances in Parkinson’s disease

    Article • Expert Review of Neurotherapeutics, September 2015, Informa Healthcare

    Professor Tjalf Ziemssen

  140. Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review

    Article • PLoS ONE, September 2015, PLOS

    Professor Tjalf Ziemssen

  141. Ein Jahr Alemtuzumab – was haben wir in der Praxis gelernt? Experten-Erfahrungsaustausch zur Therapie der Multiplen Sklerose

    Article • Aktuelle Neurologie, September 2015, Thieme Publishing Group

    Professor Tjalf Ziemssen

  142. Optimizing therapy early in multiple sclerosis: An evidence-based view

    Article • Multiple Sclerosis and Related Disorders, September 2015, Elsevier

    Professor Tjalf Ziemssen

  143. Local endothelial dysfunction does not affect global endothelial function

    Article • VASA, July 2015, Hogrefe Publishing Group

    Professor Tjalf Ziemssen

  144. The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

    Article • BMC Neurology, June 2015, Springer Science + Business Media

    Professor Tjalf Ziemssen

  145. Insulin is a key determinant of elevated retinal arteriolar flicker response in insulin-resistant individuals

    Article • Diabetologia, May 2015, Springer Science + Business Media

    Professor Tjalf Ziemssen

  146. Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial

    Article • Cardiology, May 2015, Karger Publishers

    Professor Tjalf Ziemssen

  147. Acute hyperlipidemia but not hyperhomocysteinemia impairs reflex regulation of the cardiovascular system

    Article • Atherosclerosis Supplements, May 2015, Elsevier

    Professor Tjalf Ziemssen

  148. Different responses of the retinal and cutaneous microcirculation to transient dysmetabolic conditions

    Article • Atherosclerosis Supplements, May 2015, Elsevier

    Professor Tjalf Ziemssen

  149. Immunoadsorption with regenerating systems in neurological disorders – A single center experience

    Article • Atherosclerosis Supplements, May 2015, Elsevier

    Professor Tjalf Ziemssen

  150. Dynamic formation of macular microcysts independent of vitreous traction changes

    Article • Neurology, January 2015, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  151. MS-Dokumentation, MS-Register und MS-Management

    Article • January 2015, Elsevier

    Professor Tjalf Ziemssen

  152. Metabolische Störungen

    Article • January 2015, Springer Science + Business Media

    Professor Tjalf Ziemssen

  153. A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe

    Article • Multiple Sclerosis and Related Disorders, January 2015, Elsevier

    Professor Tjalf Ziemssen

  154. Autorenverzeichnis

    Article • January 2015, Elsevier

    Professor Tjalf Ziemssen

  155. Time for Change – Evolution of Real-world Evidence Outcome Measures in Multiple Sclerosis Exemplified by Fingolimod

    Article • European Neurological Review, January 2015, Touch Digital Media, Ltd.

    Professor Tjalf Ziemssen

  156. Therapieziele und Therapiemanagement bei schubförmigremittierender Multipler Sklerose

    Article • Nervenheilkunde, January 2015, Thieme Publishing Group

    Professor Tjalf Ziemssen

  157. Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

    Article • Deutsche Zeitschrift für Nervenheilkunde, November 2014, Springer Science + Business Media

    Professor Tjalf Ziemssen

  158. Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination

    Article • Molecular Psychiatry, November 2014, Nature

    Professor Tjalf Ziemssen

  159. Dendritic cells are specifically affected by different immunomodulatory treatment strategies in multiple sclerosis

    Article • Journal of Neuroimmunology, October 2014, Elsevier

    Professor Tjalf Ziemssen

  160. Time matters – Acute stress response and glucocorticoid sensitivity in early multiple sclerosis

    Article • Brain Behavior and Immunity, October 2014, Elsevier

    Professor Tjalf Ziemssen

  161. Accumulation and therapeutic modulation of 6-sulfo LacNAc + dendritic cells in multiple sclerosis

    Article • Neurology Neuroimmunology & Neuroinflammation, September 2014, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  162. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

    Article • Deutsche Zeitschrift für Nervenheilkunde, August 2014, Springer Science + Business Media

    Professor Tjalf Ziemssen

  163. Axon-Reflex-basierte Nervenmessverfahren in der Diagnostik autonomer Neuropathie

    Article • Der Nervenarzt, July 2014, Springer Science + Business Media

    Professor Tjalf Ziemssen

  164. Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson’s disease

    Article • Journal of Neural Transmission, July 2014, Springer Science + Business Media

    Professor Tjalf Ziemssen

  165. Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease

    Article • BMC Neurology, June 2014, Springer Science + Business Media

    Professor Tjalf Ziemssen

  166. Attenuated brain-derived neurotrophic factor and hypertrophic remodelling: the SABPA study

    Article • Journal of Human Hypertension, June 2014, Nature

    Professor Tjalf Ziemssen, Professor Leoné Malan

  167. Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial

    Article • Heart and Vessels, February 2014, Springer Science + Business Media

    Professor Tjalf Ziemssen

  168. Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma

    Article • February 2014, Bioscientifica

    Dr Christina Pamporaki, Professor Tjalf Ziemssen

  169. Attenuated NOx responses and myocardial ischemia, a possible risk for structural vascular disease in African men: the SABPA study

    Article • Journal of Human Hypertension, January 2014, Nature

    Professor Tjalf Ziemssen, Professor Leoné Malan

  170. Management of fingolimod in clinical practice

    Article • Clinical Neurology and Neurosurgery, December 2013, Elsevier

    Professor Tjalf Ziemssen

  171. Perspectives of an innovative ophthalmological technology: Optical coherence tomography (OCT) – What should be of interest to the neurologist?

    Article • Clinical Neurology and Neurosurgery, December 2013, Elsevier

    Professor Tjalf Ziemssen

  172. Nocturnal Blood Pressure, 3-Methoxy-4-hydroxyphenylglycol and Carotid Intima-media Thickness: The SABPA Study

    Article • Heart Lung and Circulation, November 2013, Elsevier

    Professor Leoné Malan, Professor Tjalf Ziemssen

  173. Das Herz in der Tintenfischfalle

    Article • MMW - Fortschritte der Medizin, November 2013, Springer Science + Business Media

    Professor Tjalf Ziemssen

  174. Mehr als dokumentieren: computerunterstütztes Patientenmanagement

    Article • DNP - Der Neurologe und Psychiater, October 2013, Springer Science + Business Media

    Professor Tjalf Ziemssen

  175. Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2013, BMJ

    Professor Tjalf Ziemssen

  176. Effects of Acute and Chronic Stress on the L-Arginine Nitric Oxide Pathway in Black and White South Africans

    Article • Psychosomatic Medicine, October 2013, Wolters Kluwer Health

    Professor Leoné Malan, Professor Tjalf Ziemssen

  177. Defensive active coping facilitates chronic hyperglycaemia and endothelial dysfunction in African men: The SABPA study

    Article • International Journal of Cardiology, September 2013, Elsevier

    Professor Tjalf Ziemssen, Professor Leoné Malan

  178. Therapeutic Decisions in Multiple Sclerosis

    Article • JAMA Neurology, August 2013, American Medical Association (AMA)

    Professor Tjalf Ziemssen

  179. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

    Article • The Lancet Neurology, August 2013, Elsevier

    Professor Tjalf Ziemssen

  180. Neuroborreliosis during natalizumab treatment in multiple sclerosis

    Article • Neurology, July 2013, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  181. Recent perspectives in neurology

    Article • Journal of Neural Transmission, July 2013, Springer Science + Business Media

    Professor Tjalf Ziemssen

  182. Trigonometric regressive spectral analysis: an innovative tool for evaluating the autonomic nervous system

    Article • Journal of Neural Transmission, June 2013, Springer Science + Business Media

    Professor Tjalf Ziemssen

  183. Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients

    Article • Journal of Neural Transmission, June 2013, Springer Science + Business Media

    Professor Tjalf Ziemssen

  184. Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors

    Article • Multiple Sclerosis Journal, May 2013, SAGE Publications

    Professor Tjalf Ziemssen

  185. Fingolimod — Sicherheitsdaten und Management in der klinischen Praxis

    Article • DNP - Der Neurologe und Psychiater, May 2013, Springer Science + Business Media

    Professor Tjalf Ziemssen

  186. Cortisol Awakening Response Is Linked to Disease Course and Progression in Multiple Sclerosis

    Article • PLoS ONE, April 2013, PLOS

    Professor Tjalf Ziemssen

  187. Defensive coping facilitates higher blood pressure and early sub-clinical structural vascular disease via alterations in heart rate variability: The SABPA study

    Article • Atherosclerosis, April 2013, Elsevier

    Professor Tjalf Ziemssen, Professor Leoné Malan

  188. Chronisch krank und ohne Arbeit? Eine aktuelle Analyse zur Erwerbstätigkeit bei Multipler Sklerose

    Article • Fortschritte der Neurologie · Psychiatrie, February 2013, Thieme Publishing Group

    Professor Tjalf Ziemssen

  189. Modern communication technology skills of patients with multiple sclerosis

    Article • Multiple Sclerosis Journal, February 2013, SAGE Publications

    Professor Tjalf Ziemssen

  190. Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells

    Article • Atherosclerosis Supplements, January 2013, Elsevier

    Professor Tjalf Ziemssen

  191. Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study

    Article • Experimental & Translational Stroke Medicine, January 2013, Springer Science + Business Media

    Professor Tjalf Ziemssen

  192. The sensory channel of presentation alters subjective ratings and autonomic responses toward disgusting stimuli—Blood pressure, heart rate and skin conductance in response to visual, auditory, haptic and olfactory presented disgusting stimuli

    Article • Frontiers in Human Neuroscience, January 2013, Frontiers

    Professor Tjalf Ziemssen

  193. Die Anwendung von Multi-Touch-Gesten in Patientenmanagementsystemen

    Article • January 2013, Springer Science + Business Media

    Professor Tjalf Ziemssen

  194. Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease

    Article • Atherosclerosis Supplements, January 2013, Elsevier

    Professor Tjalf Ziemssen

  195. Metabolomic distinction of microvascular effects of lipoprotein apheresis – A pilot study

    Article • Atherosclerosis Supplements, January 2013, Elsevier

    Professor Tjalf Ziemssen

  196. Greater cardiovascular reactivity to a cold stimulus is due to higher cold pain perception in black Africans

    Article • Journal of Hypertension, December 2012, Wolters Kluwer Health

    Professor Leoné Malan, Professor Tjalf Ziemssen

  197. Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study

    Article • Journal of Medical Internet Research, October 2012, JMIR Publications Inc.

    Professor Tjalf Ziemssen

  198. Wandel in aktueller Bewertung neuer Wirkstoffe erfordert Erhebung pharmakoökonomischer Daten: Behandlungszufriedenheit von Fingolimod (Gilenya) im Vergleich zu Erstlinientherapeutika bei Patienten mit Multipler Sklerose (PANGAEA und PEARL)

    Article • Aktuelle Neurologie, September 2012, Thieme Publishing Group

    Professor Tjalf Ziemssen

  199. 290 GREATER CARDIOVASCULAR REACTIVITY TO A COLD PRESSOR TEST IS DUE TO HIGHER COLD PAIN PERCEPTION IN BLACK AFRICANS

    Article • Journal of Hypertension, September 2012, Wolters Kluwer Health

    Professor Leoné Malan, Professor Tjalf Ziemssen

  200. 928 DEFENSIVE ACTIVE COPING FACILITATES CHRONIC HYPERGLYCEMIA AND EARLY VASCULAR STRUCTURAL CHANGES IN AFRICAN MEN

    Article • Journal of Hypertension, September 2012, Wolters Kluwer Health

    Professor Leoné Malan, Professor Tjalf Ziemssen

  201. Psychoneuroimmunology - Psyche and Autoimmunity

    Article • Current Pharmaceutical Design, August 2012, Bentham Science Publishers

    Professor Tjalf Ziemssen

  202. Neue Perspektiven eines modernen Untersuchungsverfahrens

    Article • DNP - Der Neurologe und Psychiater, June 2012, Springer Science + Business Media

    Professor Tjalf Ziemssen

  203. Modernes Therapiemanagement zur Verbesserung der Therapie mit Interferon β-1b mit MSDS 3D

    Article • Aktuelle Neurologie, May 2012, Thieme Publishing Group

    Professor Tjalf Ziemssen

  204. Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease

    Article • Movement Disorders, April 2012, Wiley

    Professor Tjalf Ziemssen

  205. Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy

    Article • Journal of Hypertension, March 2012, Wolters Kluwer Health

    Professor Leoné Malan, Professor Tjalf Ziemssen

  206. Improving patient–physician dialog: commentary on the results of the MS Choices survey

    Article • Patient Preference and Adherence, February 2012, Taylor & Francis

    Professor Tjalf Ziemssen, Prof Alessandra Lugaresi

  207. Static posturography in aging and Parkinson's disease

    Article • Frontiers in Aging Neuroscience, January 2012, Frontiers

    Professor Tjalf Ziemssen

  208. Brain activity increases blood pressure when stress perception is high

    Article • Psychophysiology, December 2011, Wiley

    Professor Leoné Malan, Professor Tjalf Ziemssen

  209. Symptom management in patients with multiple sclerosis

    Article • Journal of the Neurological Sciences, December 2011, Elsevier

    Professor Tjalf Ziemssen

  210. Cardiovascular autonomic testing in extrapyramidal disorders

    Article • Journal of the Neurological Sciences, November 2011, Elsevier

    Professor Tjalf Ziemssen

  211. Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis

    Article • Psychoneuroendocrinology, November 2011, Elsevier

    Professor Tjalf Ziemssen

  212. Multiple-Sklerose-Dokumentationssystem 3D

    Article • Der Nervenarzt, October 2011, Springer Science + Business Media

    Professor Tjalf Ziemssen

  213. Seizures Associated with Zoledronic Acid for Osteoporosis

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2011, Endocrine Society

    Professor Tjalf Ziemssen

  214. Baroreceptor sensitivity, cardiovascular responses and ECG left ventricular hypertrophy in men: The SABPA study

    Article • Blood Pressure, May 2011, Taylor & Francis

    Professor Leoné Malan, Professor Tjalf Ziemssen

  215. Treatment of dysautonomia in extrapyramidal disorders

    Article • Deutsche Zeitschrift für Nervenheilkunde, May 2011, Springer Science + Business Media

    Professor Tjalf Ziemssen

  216. Seizures after treatment with zoledronic acid for osteoporosis

    Article • Bone, May 2011, Elsevier

    Professor Tjalf Ziemssen

  217. Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders

    Article • PLoS ONE, April 2011, PLOS

    Professor Tjalf Ziemssen

  218. Determination of Baroreflex Sensitivity during the Modified Oxford Maneuver by Trigonometric Regressive Spectral Analysis

    Article • PLoS ONE, March 2011, PLOS

    Professor Tjalf Ziemssen

  219. LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients

    Article • Atherosclerosis, November 2010, Elsevier

    Professor Tjalf Ziemssen

  220. Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report

    Article • Multiple Sclerosis Journal, October 2010, SAGE Publications

    Professor Tjalf Ziemssen

  221. Psychoneuroimmunologische Aspekte des CIS

    Article • Der Nervenarzt, October 2010, Springer Science + Business Media

    Professor Tjalf Ziemssen

  222. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

    Article • Annals of Neurology, August 2010, Wiley

    Professor Tjalf Ziemssen

  223. Trigonometric Regressive Spectral Analysis Reliably Maps Dynamic Changes in Baroreflex Sensitivity and Autonomic Tone: The Effect of Gender and Age

    Article • PLoS ONE, August 2010, PLOS

    Professor Tjalf Ziemssen

  224. Therapie autonomer Dysfunktion bei Patienten mit extrapyramidalen Erkrankungen

    Article • Fortschritte der Neurologie · Psychiatrie, July 2010, Thieme Publishing Group

    Professor Tjalf Ziemssen

  225. The cold hand sign in multiple system atrophy: skin perfusion revisited

    Article • Journal of Neural Transmission, February 2010, Springer Science + Business Media

    Professor Tjalf Ziemssen

  226. Cardiovascular autonomic dysfunction in Parkinson's disease

    Article • Journal of the Neurological Sciences, February 2010, Elsevier

    Professor Tjalf Ziemssen

  227. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function

    Article • Bone Marrow Transplantation, January 2010, Nature

    Professor Tjalf Ziemssen

  228. Autonomic Function and Cerebral Autoregulation in Patients Undergoing Carotid Endarterectomy

    Article • Circulation Journal, January 2010, Japanese Circulation Society

    Professor Tjalf Ziemssen

  229. Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes

    Article • Movement Disorders, December 2009, Wiley

    Professor Tjalf Ziemssen

  230. Ethnic‐specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function

    Article • Obesity, December 2009, Wiley

    Professor Leoné Malan, Professor Tjalf Ziemssen

  231. Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis

    Article • Atherosclerosis Supplements, December 2009, Elsevier

    Professor Tjalf Ziemssen

  232. Education Research: Cognitive performance is preserved in sleep-deprived neurology residents

    Article • Neurology, November 2009, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  233. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes

    Article • Movement Disorders, October 2009, Wiley

    Professor Tjalf Ziemssen

  234. Review: Treatment of dysautonomia in extrapyramidal disorders

    Article • Therapeutic Advances in Neurological Disorders, October 2009, SAGE Publications

    Professor Tjalf Ziemssen

  235. Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis

    Article • PROTEOMICS - CLINICAL APPLICATIONS, October 2009, Wiley

    Dr Giuseppina Maccarrone, Professor Tjalf Ziemssen

  236. Comprehensive autonomic assessment does not differentiate between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy

    Article • Journal of Neural Transmission, September 2009, Springer Science + Business Media

    Professor Tjalf Ziemssen

  237. Kostenanalyse neurologischer Patienten

    Article • Der Nervenarzt, June 2009, Springer Science + Business Media

    Professor Tjalf Ziemssen

  238. Regulatorische T-Zellen bei Patienten mit Multipler Sklerose

    Article • Der Nervenarzt, June 2009, Springer Science + Business Media

    Professor Tjalf Ziemssen

  239. Valsalva manoeuvre in patients with different Parkinsonian disorders

    Article • Journal of Neural Transmission, June 2009, Springer Science + Business Media

    Professor Tjalf Ziemssen

  240. Pupillary responses to intranasal trigeminal and olfactory stimulation

    Article • Journal of Neural Transmission, May 2009, Springer Science + Business Media

    Professor Tjalf Ziemssen

  241. Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis

    Article • Multiple Sclerosis Journal, May 2009, SAGE Publications

    Professor Tjalf Ziemssen

  242. Effect of BEMER Magnetic Field Therapy on the Level of Fatigue in Patients with Multiple Sclerosis: A Randomized, Double-Blind Controlled Trial

    Article • The Journal of Alternative and Complementary Medicine, May 2009, Mary Ann Liebert Inc

    Professor Tjalf Ziemssen

  243. Treatment strategies for nonmotor manifestations of Parkinson's disease

    Article • Expert Opinion on Pharmacotherapy, April 2009, Informa Healthcare

    Professor Tjalf Ziemssen

  244. Multiple sclerosis beyond EDSS: depression and fatigue

    Article • Journal of the Neurological Sciences, February 2009, Elsevier

    Professor Tjalf Ziemssen

  245. What can we learn from failed clinical trials in multiple sclerosis?

    Article • Deutsche Zeitschrift für Nervenheilkunde, December 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  246. Potential side effect of high-dose corticosteroid relapse treatment: acute generalized exanthematous pustulosis (AGEP)

    Article • Multiple Sclerosis Journal, October 2008, SAGE Publications

    Professor Tjalf Ziemssen

  247. Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  248. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes

    Article • Journal of Neural Transmission, September 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  249. Autonomic dysfunction in different subtypes of multiple system atrophy

    Article • Movement Disorders, September 2008, Wiley

    Professor Tjalf Ziemssen

  250. Autonomic dysfunction in patients with progressive supranuclear palsy

    Article • Movement Disorders, September 2008, Wiley

    Professor Tjalf Ziemssen

  251. Moderne Immuntherapie der multiplen Sklerose

    Article • Aktuelle Neurologie, May 2008, Thieme Publishing Group

    Professor Tjalf Ziemssen

  252. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study

    Article • International Ophthalmology, April 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  253. Influence of ECG Sampling Frequency on Spectral Analysis of RR Intervals and Baroreflex Sensitivity Using the EUROBAVAR Data set

    Article • Journal of Clinical Monitoring and Computing, March 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  254. Therapieadhärenz in der neurologischen Praxis

    Article • Der Nervenarzt, March 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  255. Erratum

    Article • Deutsche Zeitschrift für Nervenheilkunde, February 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  256. Review: Brain—immune communication psychoneuroimmunology of multiple sclerosis

    Article • Multiple Sclerosis Journal, January 2008, SAGE Publications

    Professor Tjalf Ziemssen

  257. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

    Article • Health and Quality of Life Outcomes, January 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  258. Pharmacokinetic/Pharmacodynamic Modelling of Venlafaxine

    Article • Clinical Pharmacokinetics, January 2008, Springer Science + Business Media

    Professor Tjalf Ziemssen

  259. The Effects of Venlafaxine on Autonomic Functions in Healthy Volunteers

    Article • Journal of Clinical Psychopharmacology, December 2007, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  260. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes

    Article • Movement Disorders, October 2007, Wiley

    Professor Tjalf Ziemssen

  261. Non-motor dysfunction in Parkinson's disease

    Article • Parkinsonism & Related Disorders, August 2007, Elsevier

    Professor Tjalf Ziemssen

  262. Glatiramer acetate: Mechanisms of action in multiple sclerosis

    Article • Autoimmunity Reviews, August 2007, Elsevier

    Professor Tjalf Ziemssen

  263. Intravitreous bevacizumab and blood pressure: does ‘safe’ mean ‘safe enough’?

    Article • Acta Ophthalmologica Scandinavica, August 2007, Wiley

    Professor Tjalf Ziemssen

  264. A New Line Immunoassay for the Multiparametric Detection of Antiganglioside Autoantibodies in Patients with Autoimmune Peripheral Neuropathies

    Article • Annals of the New York Academy of Sciences, August 2007, Wiley

    Professor Tjalf Ziemssen

  265. Psychoneuroimmunology – Cross-talk between the immune and nervous systems

    Article • Deutsche Zeitschrift für Nervenheilkunde, May 2007, Springer Science + Business Media

    Professor Tjalf Ziemssen

  266. Intravitreous bevacizumab and blood pressure: does ‘safe’ mean ‘safe enough’?

    Article • Acta Ophthalmologica Scandinavica, April 2007, Wiley

    Professor Tjalf Ziemssen

  267. The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects

    Article • Clinical Autonomic Research, March 2007, Springer Science + Business Media

    Professor Tjalf Ziemssen

  268. Stroke-Induced Immunodepression: Experimental Evidence and Clinical Relevance

    Article • Stroke, January 2007, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  269. Glatiramer Acetate: Mechanisms of Action in Multiple Sclerosis

    Article • January 2007, Elsevier

    Professor Tjalf Ziemssen

  270. Autonome Dysfunktion beim idiopathischen Parkinson-Syndrom und der Multisystematrophie

    Article • Aktuelle Neurologie, September 2006, Thieme Publishing Group

    Professor Tjalf Ziemssen

  271. Multiple Sklerose

    Article • Der Ophthalmologe, July 2006, Springer Science + Business Media

    Professor Tjalf Ziemssen

  272. Untersuchung zur Genauigkeit der Abtastung von EKG-Signalen für eine nachfolgende Spektralanalyse kontinuierlich gemessener RR-Intervalle im Schlaflabor

    Article • Somnologie - Schlafforschung und Schlafmedizin, May 2006, Springer Science + Business Media

    Professor Tjalf Ziemssen

  273. Untersuchung zur Genauigkeit der Abtastung von EKG-Signalen fur eine nachfolgende Spektralanalyse kontinuierlich gemessener RR-Intervalle im Schlaflabor. Assessment of Accuracy of ECG Signal Sampling for Spectral Analysis of Beat-to-Beat Recorded R-R I...

    Article • Somnologie - Schlafforschung und Schlafmedizin, May 2006, Springer Science + Business Media

    Professor Tjalf Ziemssen

  274. Multiple sclerosis and the autonomic nervous system

    Article • Deutsche Zeitschrift für Nervenheilkunde, February 2006, Springer Science + Business Media

    Professor Tjalf Ziemssen

  275. Pandysautonomie als Erstmanifestation eines Plasmozytoms

    Article • Aktuelle Neurologie, January 2006, Thieme Publishing Group

    Professor Tjalf Ziemssen

  276. Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2005, Springer Science + Business Media

    Professor Tjalf Ziemssen

  277. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE)

    Article • Autoimmunity Reviews, September 2005, Elsevier

    Professor Tjalf Ziemssen

  278. Autoimmune CD4+ T Cell Memory: Lifelong Persistence of Encephalitogenic T Cell Clones in Healthy Immune Repertoires

    Article • The Journal of Immunology, June 2005, The American Association of Immunologists

    Professor Tjalf Ziemssen

  279. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy

    Article • Journal of the Neurological Sciences, June 2005, Elsevier

    Professor Tjalf Ziemssen

  280. Autonome Störungen

    Article • January 2005, Elsevier

    Professor Tjalf Ziemssen

  281. The Activation Status of Neuroantigen-specific T Cells in the Target Organ Determines the Clinical Outcome of Autoimmune Encephalomyelitis

    Article • The Journal of Experimental Medicine, January 2004, Rockefeller University Press

    Professor Tjalf Ziemssen

  282. Neuroprotection and Glatiramer Acetate: The Possible Role in the Treatment of Multiple Sclerosis

    Article • January 2004, Springer Science + Business Media

    Professor Tjalf Ziemssen

  283. Adult polyglucosan body disease: A postmortem correlation study

    Article • Neurology, July 2003, Wolters Kluwer Health

    Professor Tjalf Ziemssen

  284. Morbus Parkinson — Gehirnerkrankung oder Ganzkörpererkrankung?

    Article • January 2003, Springer Science + Business Media

    Professor Tjalf Ziemssen

  285. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy

    Article • Brain, November 2002, Oxford University Press (OUP)

    Professor Tjalf Ziemssen

  286. Behandlung der Multiplen Sklerose mit Glatiramer-Azetat

    Article • Der Nervenarzt, April 2002, Springer Science + Business Media

    Professor Tjalf Ziemssen

  287. Graves’ disease after treatment with Alemtuzumab for multiple sclerosis

    Article • HORMONES, February 2002, Hellenic Endocrine Society

    Professor Tjalf Ziemssen

  288. Phospholipase A2 degradation products modulate epithelial and stromal 5?-reductase activity of human benign prostatic hyperplasia in vitro

    Article • The Prostate, December 2001, Wiley

    Professor Tjalf Ziemssen

  289. In vitro modulation of steroid 5α-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia

    Article • Steroids, June 2001, Elsevier

    Professor Tjalf Ziemssen

  290. Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

    Article • Drug Safety, January 2001, Springer Science + Business Media

    Professor Tjalf Ziemssen

  291. Posttranslationale Regulationsmöglichkeiten membrangebundener Enzyme am Beispiel der prostatischen 5α-Reduktase

    Article • LaboratoriumsMedizin, January 1999, De Gruyter

    Professor Tjalf Ziemssen